Recently, several clinical studies using 177Lu, labeled to prostate-specific membrane antigen (PSMA), have shown encouraging results in the treatment of aggressive metastatic prostate cancer [5–8]. This evidence concerns the gene FOLH1 and metastatic prostate carcinoma.